Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease

Hepatology

Volumn 46, Issue 4, 2007, Pages 1138-1145

  Montano Loza, Aldo J ^a   Carpenter, Herschel A ^a   Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; HLA DR ANTIGEN; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DRUG MEGADOSE; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BILIRUBIN; DISEASE PROGRESSION; FEMALE; HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; LIVER; LIVER FAILURE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 36349017310     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21787     Document Type: Article

References (58)

1. Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-833.
2. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976;8:221-227.
3. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824.
4. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. HEPATOLOGY 1999;30:1381-1386.
5. Alvarez F, Ciocca M, Canero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-227.
6. Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-1327.
7. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-776.
8. Aqel BA, Machicao V, Rosser B1 Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-809.
9. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-375.
10. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-326.
11. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate moferil and tacrolimus. Liver Int. 2005;25:723-727.
12. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-825.
13. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for auroimmune hepatitis - report of three cases. Z Gastroenterol 1997;35:571-578.
14. Burak KW, Urbanski SJ, Swain MG. Successful rreatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-993.
15. Santos ES, Atosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006;26:625-629.
16. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenrerology 2000;119:1312-1316.
17. Carmassi F, Morale R, Puccetti R, Pistelli F, Palla R, Bevilacqua G, et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 1992;10:13-17.
18. Swada K, Ohnishi K, Kosaka T, Chikano S, Egashira A, Okui M, et al. Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J Gastroenterol 1997;32:689-695.
19. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
20. Horsmans Y, Piret A, Brenard R, Rahier J, Geubel AP. Autoimmune chronic active hepatitis responsive to immunosuppressive rherapy evolving into a typical primary biliary cirrhosis syndrome: a case report. J Hepatol 1994;21:194-198.
21. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepat 1992;14:325-331.
22. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992;37:1606-1611.
23. Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699-705.
24. McNair ANB, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am J Gastroenterol 1998;93:777-784.
25. Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995;40:33-40.
26. DePinho RA, Goldberg CS, Lefkowirch JH. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984;86:162-165.
27. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderare degree in asymptomatic patients. HEPATOLOGY 1989;9:193-197.
28. Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. HEPATOLOGY 1997;25:317-323.
29. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-652.
30. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. HEPATOLOGY 2000;31:49-53.
31. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007;69:227-235.
32. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end srage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
33. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). HEPATOLOGY 2007;45:797-805.
34. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic porrosystemic shunts. HEPATOLOGY 2000;31:864-871.
35. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
36. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005;41:353-358.
37. Alessandria C, Ozdogan O, Guevara M, Resruccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance ro liver transplantation. HEPATOLOGY 2005;41:1282-shy; 1289.
38. Zaman MB, Hoti E, Qasim A, Maguire D, McCormick PA, Hegarty JE, et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant Proc 2006;38:2097-2098.
39. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gasrroenrerology 2005;129:1944-1953.
40. Perkins J. The MELD score as a predictor of nontransplant surgical mortality in patients with cirrhosis. Liver Transpl 2006;12:159.
41. Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system. J Gastroenterol Hepatol 2006;21:1519-1524.
42. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. HEPATOLOGY 2002;36:479-497.
43. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic acrive liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-883.
44. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-1211.
45. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. HEPATOLOGY 1996;24:1068-1073.
46. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-1696.
47. Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirecr immunofluorescence methods. Arch Pathol Lab Med 1998;122:993-999.
48. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-1295.
49. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Path 1995;19:1409-1417.
50. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-1832.
51. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WHJ. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1975;20:1087-1090.
52. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. HEPATOLOGY 1984;4:622-627.
53. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. HEPATOLOGY 2004;39:1631-1638.
54. Montano-Loza AJ, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB1*03-DRB 1*04 in type 1 autoimmune hepatitis. Liver Int 2006;26:1201-1208.
55. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characreristic (ROC) curve. Radiology 1982;143:29-36.
56. Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977;22:973-980.
57. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95:448-453.
58. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. HEPATOLOGY 2005;41:207-215.